AOD-9604 vs. Liraglutide

Category

Growth

Metabolic

CAS no.

221231-10-3

204656-20-2

Molecular weight

1815.09 g/mol

3751 g/mol

Half-life

0.4 h

13 h

Sequence

AOD-9604

AOD-9604 corresponds to the C-terminal fragment 176-191 of human growth hormone with an additional N-terminal tyrosine. In animal models, lipolytic effects without GH-typical adverse events (insulin resistance, IGF-1 rise) were reported. In humans, these preclinical findings did not translate into clinically relevant weight reduction in the four phase-2 obesity trials. The exact human mechanism of action is unclear; the GH receptor is not classically activated by the fragment.

Liraglutide

Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.

Highest evidence

Studies

3

5

of which in humans

2

4

Effects recorded

3

3

Open conflicts

1

0

Documented adverse events

1

1